BVF I GP LLC
- SEC CIK
- 0001803805
In the past year, 2 open-market sale filings worth $236.6M and no purchases.
Current role at each company
- IMUX Immunic, Inc.Director, Other: See Explanation of Responsesas of Sep 18, 2026
- XOMA XOMA Royalty Corp10% Owneras of Jul 16, 2026
- KYMR Kymera Therapeutics, Inc.Director, Other: See Remarks and Footnotesas of Jun 26, 2026
- OLMA Olema Pharmaceuticals, Inc.Director, Other: See Explanation of Responsesas of Jun 23, 2026
- MLTX MoonLake ImmunotherapeuticsDirector, 10% Owneras of Jun 22, 2026
Show 14 more companies
- RPTX Repare Therapeutics Inc.10% Owneras of Jan 30, 2026
- EPIX ESSA Pharma Inc.10% Owneras of Oct 14, 2025
- CBIO Crescent Biopharma, Inc.10% Owneras of Jun 17, 2025
- ALLK Allakos Inc.Other: See Explanation of Responsesas of May 19, 2025
- PVLA Palvella Therapeutics, Inc.Other: See Explanation of Responsesas of Dec 17, 2024
- FDMT 4D Molecular Therapeutics, Inc.Other: See Explanation of Responsesas of Nov 13, 2024
- THRD Third Harmonic Bio, Inc.Other: See Explanation of Responsesas of Oct 31, 2024
- ELDN Eledon Pharmaceuticals, Inc.Other: See Explanation of Responsesas of Oct 31, 2024
- Rain Oncology Inc.Director, Other: See Remarks; Former 10% Owneras of Jan 29, 2024
- PNT POINT Biopharma Global Inc.Other: Former 10% Owneras of Dec 20, 2023
- CTIC Cti Biopharma CorpDirector, 10% Owner, Other: See Explanation of Responsesas of Jun 28, 2023
- GPCR Structure Therapeutics Inc.Other: See explanation of responsesas of May 12, 2023
- CGEM Cullinan Therapeutics, Inc.Other: See Explanation of Responsesas of Jan 19, 2023
- MRUS Merus N.V.Other: See Explanation of Responsesas of Oct 8, 2021
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $236.6M
- 2 filings
- Net
- −$236.6M
- Bought minus sold
- Companies
- 2
- With open-market trades
Trades
Every Form 4 that lists BVF I GP LLC as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
KYMR Kymera Therapeutics, Inc.
Director, Other: See Remarks and Footnotes14 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 26, 2026 (view filing)6:48 PM ET | Jun 26 | Same day | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | SSaleCommon Stock, $0.0001 par value | −1.58M | $106.50 | −$168.1M | −86.8%240.1K after | 3 lots |
| Jun 26, 2026 (view filing)6:48 PM ET | Jun 26 | Same day | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | SSaleCommon Stock, $0.0001 par value | −51.9K | $106.50 | −$5.52M | −39.7%78.8K after | |
| Jul 1, 2025 (view filing)6:41 PM ET | Jun 30 | 1 day | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | PPurchaseCommon Stock, $0.0001 par value | +317.2K | $44.00 | +$14.0M | +875.1%353.4K after | 3 lots |
| Aug 22, 2024 (view filing)5:06 PM ET | Aug 20 | 2 days | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | PPurchaseCommon Stock, $0.0001 par value | +358.3K | $40.75 | +$14.6M | –156.7K after | Derivative2 lots |
| Jan 9, 2024 (view filing)4:49 PM ET | Jan 5 | 4 days | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | PPurchaseCommon Stock, $0.0001 par value | +979.0K | $25.25 | +$24.7M | –52.7K after | Derivative3 lots |
| Nov 6, 2023 (view filing)6:07 PM ET | Nov 2-3 | 4 days | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | PPurchaseCommon Stock, $0.0001 par value | +414.1K | $12.80 | +$5.30M | New position294.6K after | 6 lots |
| Jan 13, 2023 (view filing)5:08 PM ET | Jan 11-12 | 2 days | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | PPurchaseCommon Stock, $0.0001 par value | +41.0K | $30.51 | +$1.25M | +2.2%1.89M after | 4 lots |
| Aug 23, 2022 (view filing)5:35 PM ET | Aug 22 | 1 day | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | PPurchaseCommon Stock, $0.0001 par value | +545.5K | $26.00 | +$14.2M | New position257.8K after | 3 lots |
| May 31, 2022 (view filing)7:50 PM ET | May 26-27 | 5 days | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | PPurchaseCommon Stock, $0.0001 par value | +289.4K | $14.34 | +$4.15M | New position230.6K after | 6 lots |
| May 24, 2022 (view filing)8:09 PM ET | May 20 | 4 days | Biotechnology Value Fund L P and 9 othersDirector, Other: See Remarks and Footnotes | PPurchaseCommon Stock, $0.0001 par value | +10.1K | $14.00 | +$141.4K | +4.9%216.8K after | 3 lots |
MLTX MoonLake Immunotherapeutics
Director, 10% Owner2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 2, 2026 (view filing)4:48 PM ET | Mar 31 | 2 days | Biotechnology Value Fund L P and 9 othersDirector, 10% Owner | SSaleClass A Ordinary Shares, $0.0001 par value | −3.75M | $16.79 | −$63.0M | −78.3%1.04M after | 3 lots |
| Oct 8, 2024 (view filing)6:50 PM ET | Oct 4 | 4 days | Biotechnology Value Fund L P and 9 othersDirector, 10% Owner | SSaleClass A Ordinary Shares, $0.0001 par value | −2.00M | $50.00 | −$100.0M | −60.8%1.29M after | 3 lots |
EPIX ESSA Pharma Inc.
10% Owner1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 7, 2025 (view filing)4:36 PM ET | Aug 5 | 2 days | Biotechnology Value Fund L P and 9 others10% Owner | SSale | −156 | $1.88 | −$292.95 | 0.0%560.8K after | 3 lots |
XOMA XOMA Royalty Corp
10% Owner6 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 20, 2025 (view filing)6:56 PM ET | May 16 | 4 days | Biotechnology Value Fund L P and 9 others10% Owner | SSaleCommon Stock, $0.0075 par value per share | −392.7K | $27.10 | −$10.6M | −23.7%1.27M after | 2 lots |
| Jan 28, 2025 (view filing)5:23 PM ET | Jan 24 | 4 days | Biotechnology Value Fund L P and 9 others10% Owner | SSaleCommon Stock, $0.0075 par value per share | −500.7K | $26.10 | −$13.1M | −100.0%0 after | 3 lots |
| Jan 28, 2025 (view filing)5:23 PM ET | Jan 24 | 4 days | Biotechnology Value Fund L P and 9 others10% Owner | SSaleCommon Stock, $0.0075 par value per share | −150.0K | $26.10 | −$3.91M | −100.0%0 after | |
| Jan 9, 2023 (view filing)5:44 PM ET | Jan 5-6 | 4 days | Biotechnology Value Fund L P and 9 othersDirector, 10% Owner | PPurchaseCommon Stock, $0.0075 par value per share | +22.2K | $18.91 | +$420.7K | +1.4%1.62M after | 4 lots |
| Sep 27, 2022 (view filing)7:22 PM ET | Sep 23-27 | 4 days | Biotechnology Value Fund L P and 9 othersDirector, 10% Owner | PPurchaseCommon Stock, $0.0075 par value per share | +24.6K | $16.61 | +$409.3K | +1.6%1.60M after | 6 lots |
| Sep 16, 2022 (view filing)6:30 PM ET | Sep 14-16 | 2 days | Biotechnology Value Fund L P and 9 othersDirector, 10% Owner | PPurchaseCommon Stock, $0.0075 par value per share | +56.3K | $17.59 | +$990.7K | +3.3%1.77M after | 4 lots |
THRD Third Harmonic Bio, Inc.
Other: See Explanation of Responses2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 31, 2024 (view filing)5:53 PM ET | Oct 29 | 2 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | SSale | −1.00M | $14.30 | −$14.3M | −85.0%176.7K after | 3 lots |
| Dec 22, 2022 (view filing)6:49 PM ET | Dec 20 | 2 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchase | +214.1K | $4.11 | +$879.5K | +785.7%241.3K after | 3 lots |
ELDN Eledon Pharmaceuticals, Inc.
Other: See Explanation of Responses5 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 31, 2024 (view filing)5:52 PM ET | Oct 29 | 2 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchaseCommon Stock, $0.001 par value | +4.75M | $3.65 | +$17.3M | –838.5K after | Derivative3 lots |
| May 13, 2024 (view filing)5:04 PM ET | May 9 | 4 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchaseCommon Stock, $0.001 par value | +1.93M | – | – | New position220.5K after | 3 lots |
| May 13, 2024 (view filing)5:04 PM ET | May 9 | 4 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchaseCommon Stock, $0.001 par value | +5.93M | – | – | –232.1K after | Derivative3 lots |
| May 9, 2023 (view filing)8:25 PM ET | May 5 | 4 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchaseCommon Stock, $0.001 par value | +1.98M | – | – | New position145.0K after | 3 lots |
| May 9, 2023 (view filing)8:25 PM ET | May 5 | 4 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchaseCommon Stock, $0.001 par value | +9.59M | – | – | –252.3K after | Derivative6 lots |
PNT POINT Biopharma Global Inc.
Other: Former 10% Owner1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 20, 2023 (view filing)6:09 PM ET | Dec 18 | 2 days | Biotechnology Value Fund L P and 9 othersOther: Former 10% Owner | SSaleCommon Stock, $0.0001 par value | −17.2M | $12.45 | −$213.7M | −100.0%0 after | 3 lots |
RPTX Repare Therapeutics Inc.
10% Owner6 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 17, 2023 (view filing)4:54 PM ET | Nov 15-16 | 2 days | Biotechnology Value Fund L P and 9 others10% Owner | PPurchaseCommon Shares, no par value | +1.23M | $5.09 | +$6.25M | New position548.9K after | 6 lots |
| Nov 3, 2023 (view filing)5:37 PM ET | Nov 2 | 1 day | Biotechnology Value Fund L P and 9 others10% Owner | PPurchaseCommon Shares, no par value | +783.7K | $3.60 | +$2.82M | New position485.1K after | 3 lots |
| Jun 15, 2022 (view filing)6:15 PM ET | Jun 13 | 2 days | Biotechnology Value Fund L P and 9 others10% Owner | PPurchaseCommon Shares, no par value | +149.2K | $12.73 | +$1.90M | +56.6%412.6K after | 3 lots |
| Jun 6, 2022 (view filing)6:14 PM ET | Jun 2-6 | 4 days | Biotechnology Value Fund L P and 9 others10% Owner | PPurchaseCommon Shares, no par value | +1.84M | $11.90 | +$21.9M | New position406.4K after | 9 lots |
| May 20, 2022 (view filing)6:09 PM ET | May 18 | 2 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchaseCommon Shares, no par value | +420.0K | $8.50 | +$3.57M | New position313.4K after | 3 lots |
| Jan 21, 2022 (view filing)5:12 PM ET | Jan 19 | 2 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchaseCommon Shares, no par value | +998.0K | $14.10 | +$14.1M | New position307.6K after | 3 lots |
OLMA Olema Pharmaceuticals, Inc.
Director, Other: See Explanation of Responses3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 14, 2023 (view filing)4:25 PM ET | Sep 12 | 2 days | Biotechnology Value Fund L P and 9 othersDirector, Other: See Explanation of Responses | PPurchaseCommon stock, $0.0001 par value | +1.51M | $9.84 | +$14.8M | New position524.2K after | 3 lots |
| Jun 14, 2022 (view filing)4:46 PM ET | Jun 10 | 4 days | Biotechnology Value Fund L P and 9 othersDirector, Other: See Explanation of Responses | PPurchaseCommon stock, $0.0001 par value | +200.0K | $4.03 | +$806.9K | +7.4%2.91M after | 2 lots |
| Dec 2, 2021 (view filing)8:45 PM ET | Nov 30 | 2 days | BVF Partners L P and 9 othersDirector, 10% Owner | PPurchaseCommon stock, $0.0001 par value | +739.7K | $9.39 | +$6.95M | New position471.4K after | 3 lots |
Rain Oncology Inc.
Director, Other: See Remarks; Former 10% Owner5 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 10, 2022 (view filing)6:31 PM ET | Nov 8 | 2 days | Biotechnology Value Fund L P and 9 othersDirector, Other: See Explanation of Responses | PPurchaseNon-Voting Common Stock, $0.001 par value | +1.71M | $5.83 | +$9.97M | New position341.5K after | 3 lots |
| Jan 10, 2022 (view filing)6:03 PM ET | Jan 6-7 | 4 days | BVF Partners L P and 9 othersDirector, 10% Owner, Other: See Remarks | PPurchaseCommon Stock, $0.001 par value | +557.7K | $12.00 | +$6.69M | New position185.4K after | 4 lots |
| Sep 23, 2021 (view filing)8:05 PM ET | Sep 21 | 2 days | BVF Partners L P and 9 othersDirector, 10% Owner, Other: See Remarks | PPurchaseCommon Stock, $0.001 par value | +11.0K | $13.94 | +$153.8K | +6.9%170.6K after | 3 lots |
| Sep 15, 2021 (view filing)5:23 PM ET | Sep 13 | 2 days | BVF Partners L P and 9 othersDirector, 10% Owner, Other: See Remarks | PPurchaseCommon Stock, $0.001 par value | +392.3K | $16.49 | +$6.47M | New position170.0K after | 3 lots |
| Jul 6, 2021 (view filing)7:34 PM ET | Jul 1-6 | 5 days | BVF Partners L P and 9 othersDirector, 10% Owner, Other: See Remarks | PPurchaseCommon Stock, $0.001 par value | +587.0K | $15.47 | +$9.08M | New position149.5K after | 6 lots |
CTIC Cti Biopharma Corp
Director, 10% Owner, Other: See Explanation of Responses2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2022 (view filing)5:52 PM ET | Aug 9 | 2 days | Biotechnology Value Fund L P and 9 othersDirector, 10% Owner, Other: See Explanation of Responses | SSaleCommon Stock, par value $0.001 | −7.21M | $6.12 | −$44.1M | −99.7%19.8K after | 3 lots |
| Aug 11, 2022 (view filing)5:52 PM ET | Aug 9 | 2 days | Biotechnology Value Fund L P and 9 othersDirector, 10% Owner, Other: See Explanation of Responses | SSaleCommon Stock, par value $0.001 | −1.29M | $6.12 | −$7.89M | −99.5%6.15K after |
CGEM Cullinan Therapeutics, Inc.
Other: See Explanation of Responses3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 3, 2022 (view filing)6:24 PM ET | Jun 1 | 2 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchase | +751.4K | $11.00 | +$8.26M | New position364.2K after | 3 lots |
| May 16, 2022 (view filing)7:34 PM ET | May 12-13 | 4 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchase | +1.11M | $9.07 | +$10.1M | New position319.4K after | 5 lots |
| Apr 5, 2022 (view filing)6:45 PM ET | Apr 1 | 4 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | PPurchase | +276.0K | $10.75 | +$2.97M | +14.4%2.20M after | 2 lots |
MRUS Merus N.V.
Other: See Explanation of Responses2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 8, 2021 (view filing)9:24 PM ET | Oct 7-8 | 1 day | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | SSaleCommon Shares, (euro)0.09 nominal value per share | −1.13M | $27.56 | −$31.2M | −83.0%232.7K after | 6 lots |
| Jul 7, 2021 (view filing)4:49 PM ET | Jul 2 | 5 days | Biotechnology Value Fund L P and 9 othersOther: See Explanation of Responses | SSaleCommon Shares, (euro)0.09 nominal value per share | −2.19M | $20.75 | −$45.4M | −87.5%311.2K after | 3 lots |